SLU-PP-332 is a drug that mimics the effects of exercise, directing to augmented energy expenditure and closer body fat metabolism.

SLU-PP-332 is a synthetic ERR agonist that has been shown to reduce fat mass and improve glucose metabolism in mice models of obesity. It is being developed as a potential treatment for diseases such as type 2 diabetes, obesity, and kidney disease.